<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFIZOX- ceftizoxime sodiumÂ injection, powder, lyophilized, for solutionÂ </strong><br>Fujisawa Healthcare, Inc.<br></p></div>
<h1>CefizoxÂ®<br>(CEFTIZOXIME FOR INJECTION, USP)</h1>
<div class="Contents">
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<p class="First"><br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_80499F45-3807-453F-8394-15237C89196B"></a><a name="section-3"></a><p></p>
<h1>For Intravenous Infusion</h1>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_4305B2DC-3C2B-4929-844E-3C6171F72ED7"></a><a name="section-4"></a><p></p>
<h1>Description</h1>
<p class="First">Cefizox<span class="Sup">Â®</span> (ceftizoxime for injection, USP) is a sterile, semisynthetic, broadâ€?spectrum, betaâ€?lactamase resistant cephalosporin antibiotic for parenteral (IV, IM) administration. It is the sodium salt of [6RÂ­[6a,7Î²(Z)]]â€?7â€?[[(2,3â€?dihydroâ€?2â€?iminoâ€?4â€? thiazolyl) (methoxyimino) acetyl] amino]â€?8â€?oxoâ€?5â€?thiaâ€?1â€?azabicyclo [4.2.0] octâ€?2â€?eneâ€?2â€?carboxylic acid. Its sodium content is approximately 60 mg (2.6 mEq) per gram of ceftizoxime activity.</p>
<p>It has the following structural formula:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0013824B-6AEE-4DA4-AFFD-35BC6BF19D91&amp;name=cefizox-01.jpg"></div>
<p><span class="Bold">C<span class="Sub">13</span>H<span class="Sub">12</span>N<span class="Sub">5</span>NaO<span class="Sub">5</span>S<span class="Sub">2</span></span></p>
<p>Â </p>
<p><span class="Bold">405.38</span></p>
<p>Â </p>
<p>Ceftizoxime for injection, USP is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline powder.</p>
<p>Cefizox is supplied in ADD-vantage<span class="Sup">Â®</span>Â  vials as ceftizoxime sodium equivalent to 1 gram or 2 grams ceftizoxime.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_79D0E2C5-532C-4418-BC75-D4B4322F2B62"></a><a name="section-5"></a><p></p>
<h1>Clinical Pharmacology</h1>
<p class="First">Following IV administration of 1, 2, and 3 gram doses of Cefizox to normal volunteers, the following serum levels were obtained.</p>
<a name="ID_3143A510-F8B9-46C1-B915-CBA13DA92020"></a><table border="single" frame="hsides" width="532">
<caption><span>Serum Concentrations After Intravenous Administration</span></caption>
<col width="16.917%">
<col width="10.150%">
<col width="13.158%">
<col width="14.474%">
<col width="14.474%">
<col width="8.271%">
<col width="9.211%">
<col width="13.346%">
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Not Done</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td align="center" colspan="8"><p class="First">Serum Concentration (Âµg/mL)</p></td></tr>
<tr>
<td align="left" valign="top">Dose</td>
<td align="center" valign="top">5 min</td>
<td align="center" valign="top">10 min</td>
<td align="center" valign="top">30 min</td>
<td align="center" valign="top">1 hr</td>
<td align="center" valign="top">2 hr</td>
<td align="center" valign="top">4 hr</td>
<td align="center" valign="top">8 hr</td>
</tr>
<tr>
<td align="left" valign="top">1 gram</td>
<td align="center" valign="top"><a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></td>
<td align="center" valign="top"><a href="#footnote-1" class="Sup">*</a></td>
<td align="center" valign="top">60.5</td>
<td align="center" valign="top">38.9</td>
<td align="center" valign="top">21.5</td>
<td align="center" valign="top">8.4</td>
<td align="center" valign="top">1.4</td>
</tr>
<tr>
<td align="left" valign="top">2 grams</td>
<td align="center" valign="top">131.8</td>
<td align="center" valign="top">110.9</td>
<td align="center" valign="top">77.5</td>
<td align="center" valign="top">53.6</td>
<td align="center" valign="top">33.1</td>
<td align="center" valign="top">12.1</td>
<td align="center" valign="top">2.0</td>
</tr>
<tr class="Last">
<td align="left" valign="top">3 grams</td>
<td align="center" valign="top">221.1</td>
<td align="center" valign="top">174.0</td>
<td align="center" valign="top">112.7</td>
<td align="center" valign="top">83.9</td>
<td align="center" valign="top">47.4</td>
<td align="center" valign="top">26.2</td>
<td align="center" valign="top">4.8</td>
</tr>
</tbody>
</table>
<p>A serum halfâ€?life of approximately 1.7 hours was observed after IV or IM administration.</p>
<p>Cefizox is 30% protein bound.</p>
<p>Cefizox is not metabolized, and is excreted virtually unchanged by the kidneys in 24 hours. This provides a high urinary concentration. Concentrations greater than 6000 Î¼g/mL have been achieved in the urine by 2 hours after a 1 gram dose of Cefizox intravenously. Probenecid slows tubular secretion and produces even higher serum levels, increasing the duration of measurable serum concentrations.</p>
<p>Cefizox achieves therapeutic levels in various body fluids, e.g., cerebrospinal fluid (in patients with inflamed meninges), bile, surgical <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> fluid, pleural fluid, aqueous humor, ascitic fluid, peritoneal fluid, prostatic fluid and saliva, and in the following body tissues: heart, gallbladder, bone, biliary, peritoneal, prostatic, and uterine.</p>
<p>In clinical experience to date, no disulfiramâ€?like reactions have been reported with Cefizox.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_BCBBFB9C-D0F5-4387-A1ED-551EE0470960"></a><a name="section-5.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">The bactericidal action of Ceftizoxime results from inhibition of cellâ€?wall synthesis. Ceftizoxime is highly resistant to a broad spectrum of betaâ€?lactamases (penicillinase and cephalosporinase), including Richmond types I, II, III, TEM, and IV, produced by both aerobic and anaerobic gramâ€?positive and gramâ€?negative organisms.  Ceftizoxime  has been shown to be active against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <a href="#i4i_indications_ID_EBB5F71B-D45D-474D-9BF0-9737E3935B45">INDICATIONS AND USAGE</a> section:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_6DCDB516-06E1-4504-84B7-71D609D0CA03"></a><a name="section-5.1.1"></a><p></p>
<h3>Aerobic Gram-Positive Microorganisms</h3>
<p class="First"><span class="Italics">Staphylococcus aureus</span> (including penicillinase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p>NOTE: MethicillinÂ­resistant staphylococci are resistant to cephalosporins, including ceftizoxime.</p>
<p><span class="Italics">Staphylococcus epidermidis</span> (including penicillinase producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Streptococcus agalactiae</span></p>
<p><span class="Italics">Streptococcus pneumoniae</span></p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p>NOTE:  A streptococcal isolate that is susceptible to penicillin can be considered susceptible to ceftizoxime <span class="Sup">4</span>.</p>
<p><span class="Sup">Â </span></p>
<p>NOTE: Ceftizoxime is usually inactive against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterococcus faecalis.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_969BA0E6-3382-43FC-A72E-14F57179ABCE"></a><a name="section-5.1.2"></a><p></p>
<h3>Aerobic Gram-Negative Microorganisms</h3>
<p class="First"><span class="Italics">Enterobacter</span> spp.</p>
<p><span class="Italics">Escherichia coli</span></p>
<p><span class="Italics">Haemophilus influenzae</span> (including ampicillinÂ­resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>)</p>
<p><span class="Italics">Klebsiella pneumoniae</span></p>
<p><span class="Italics">Morganella morganii</span></p>
<p><span class="Italics">Neisseria gonorrhoeae</span></p>
<p><span class="Italics">Proteus mirabilis</span></p>
<p><span class="Italics">Proteus vulgaris</span></p>
<p><span class="Italics">Providencia rettgeri</span></p>
<p><span class="Italics">Pseudomonas aeruginosa</span></p>
<p><span class="Italics">Serratia marcescens</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_D1CC554C-F95E-4000-8960-F93D3B36F4AA"></a><a name="section-5.1.3"></a><p></p>
<h3>Anaerobic Microorganisms</h3>
<p class="First"><span class="Italics">Bacteroides</span> spp.</p>
<p><span class="Italics">Peptococcus</span> spp.</p>
<p><span class="Italics">Peptostreptococcus</span> spp.</p>
<p> The following <span class="Italics">in vitro</span> data are available, <span class="Bold Underline">but their clinical significance is unknown</span>. At least 90% of the following microorganisms exhibit an <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoint for ceftizoxime. However, the safety and effectiveness of ceftizoxime  in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_72E64401-6C74-40F0-BD85-07D9A33003BA"></a><a name="section-5.1.4"></a><p></p>
<h3> Aerobic Gram-Negative Microorganisms</h3>
<p class="First"><span class="Italics">Aeromonas hydrophila</span></p>
<p><span class="Italics">Citrobacter</span> spp.</p>
<p><span class="Italics">Moraxella</span><span class="Italics">catarrhalis</span></p>
<p><span class="Italics">Neisseria meningitidis</span></p>
<p><span class="Italics">Providencia stuartii</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_80F4C515-0304-4DAD-870B-0DF7E45AC03F"></a><a name="section-5.2"></a><p></p>
<h2><span class="Bold">Susceptibility Testing Methods:</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_B73A5B88-29FB-4E91-901F-6AD107B4B816"></a><a name="section-5.2.1"></a><p></p>
<h3>Dilution techniques:</h3>
<p class="First">Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs).  These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds.  The MICs should be determined using a standardized procedure.  Standardized procedures are based on a dilution method<span class="Sup">1</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of ceftizoxime powder.  The MIC values should be interpreted according to the following criteria:</p>
<a name="ID_91A5A46F-0C17-4D31-9630-6EDD3BD2E05E"></a><table width="0">
<col>
<col>
<tbody class="Headless">
<tr class="First"><td colspan="2">For testing non-fastidious aerobic microorganisms other than <span class="Italics">Haemophilus</span> spp., <span class="Italics">Neisseria gonorrhoeae</span>:</td></tr>
<tr>
<td><span class="Underline">MIC (Î¼g/mL)</span></td>
<td><span class="Underline">Interpretation</span></td>
</tr>
<tr>
<td>â‰¤8</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>16-32</td>
<td>Intermediate (I)</td>
</tr>
<tr class="Last">
<td>â‰¥64</td>
<td>Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Â </p>
<a name="ID_14878D95-723F-46EB-A5DB-521C38DC9E23"></a><table width="0">
<col>
<col>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>These interpretative standards are applicable only to broth microdilution susceptibility testing with Haemophilus spp. using Haemophilus Test Medium.<span class="Sup">2</span>
</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€ </a></dt>
<dd>The current absence of data on resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any category other than â€œsusceptibleâ€?.  <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> yielding MIC results suggestive of a â€œnonsusceptibleâ€? category should be submitted to a reference laboratory for further testing.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">â€¡</a></dt>
<dd>These interpretative standards are applicable only to agar dilution susceptibility testing using GC agar base and 1% defined growth supplements.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td colspan="2"><p class="First">For testing <span class="Italics">Haemophilus</span> spp.Â <a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td></tr>
<tr>
<td><span class="Underline">MIC (Î¼g/mL)</span></td>
<td>
<span class="Underline">Interpretation</span>Â <a name="footnote-reference-3" href="#footnote-3" class="Sup">â€ </a>
</td>
</tr>
<tr>
<td>â‰¤2</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr><td colspan="2"></td></tr>
<tr><td colspan="2"><p class="First">For testing <span class="Italics">Neisseria gonorrhoeae</span>Â <a name="footnote-reference-4" href="#footnote-4" class="Sup">â€¡</a></p></td></tr>
<tr>
<td><span class="Underline">MIC (Î¼g/mL)</span></td>
<td>
<span class="Underline">Interpretation</span>Â <a href="#footnote-3" class="Sup">â€ </a>
</td>
</tr>
<tr class="Last">
<td>â‰¤0.5</td>
<td>Susceptible (S)</td>
</tr>
</tbody>
</table>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable.  A report of â€œIntermediateâ€? indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.  This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used.  This category also provides a buffer zone, which prevents small uncontrolled technical factors from causing major discrepancies in interpretation.  A report of â€œResistantâ€? indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable, other therapy should be selected.</p>
<p>Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.  Standard ceftizoxime powder should provide the following MIC values:</p>
<a name="ID_365BF7F8-B141-4B53-92E5-7E1FF92BFBE5"></a><table border="none" frame="void" width="477">
<col width="63.312%">
<col width="36.688%">
<tbody class="Headless">
<tr class="First">
<td><span class="Underline">Microorganism</span></td>
<td><p class="First"><span class="Underline">MIC(Î¼g/mL)</span></p></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Escherichia coli  </span>ATCC 25922</td>
<td align="left" valign="top">0.03â€?0.12</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Haemophilus influenzae  </span>ATCC 49247</td>
<td align="left" valign="top">0.06-0.5</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Neisseria gonorrhoeae  </span>ATCC 49226</td>
<td align="left" valign="top">0.008-0.03</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Pseudomonas aeruginosa  </span>ATCC 27853</td>
<td align="left" valign="top">16-64</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Staphylococcus aureus  </span>ATCC 29213</td>
<td align="left" valign="top">2â€?8</td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>Â </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E2B20CA5-CA59-40AF-B315-95EBB73FBD2E"></a><a name="section-5.2.2"></a><p></p>
<h3>Diffusion Techniques:</h3>
<p class="First">Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 30-Î¼g ceftizoxime to test the susceptibility of microorganisms to ceftizoxime.</p>
<p>Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30-Î¼g ceftizoxime disk should be interpreted according to the following criteria:</p>
<a name="ID_2198077C-3B2B-4246-B752-593290BD6711"></a><table width="0">
<col>
<col>
<tbody class="Headless">
<tr class="First"><td colspan="2"><p class="First">Zone diameter interpretative standard for testing non-fastidious aerobic microorganisms other than <span class="Italics">Haemophilus</span> spp. and <span class="Italics">Neisseria gonorrhoeae</span>:</p></td></tr>
<tr>
<td><span class="Underline">Zone Diameter (mm)</span></td>
<td><span class="Underline">Interpretation</span></td>
</tr>
<tr>
<td>â‰¥ 20</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>15-19</td>
<td>Intermediate (I)</td>
</tr>
<tr class="Last">
<td>â‰¤ 14</td>
<td>Resistant (R)</td>
</tr>
</tbody>
</table>
<a name="ID_57F3B99E-4F77-4218-8D4C-BD9CFF636063"></a><table width="0">
<col>
<col>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>These zone diameter standards are applicable only to susceptibility testing with <span class="Italics">Haemophilus </span>spp. using <span class="Italics">Haemophilus</span> Test Medium.<span class="Sup">3</span>
</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">â€ </a></dt>
<dd>The current absence of data on resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any category other than â€œsusceptibleâ€?.  <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> yielding MIC results suggestive of a â€œnonsusceptibleâ€? category should be submitted to a reference laboratory for further testing.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">â€¡</a></dt>
<dd>These interpretative standards are applicable only to disk diffusion testing using GC agar base and 1% defined growth supplements incubated at 5% CO<span class="Sub">2</span>.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First"><td colspan="2"><p class="First">Zone diameter interpretative standard for testing <span class="Italics">Haemophilus</span> spp.Â <a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a></p></td></tr>
<tr>
<td><span class="Underline">Zone Diameter (mm)</span></td>
<td>Â <span class="Underline">Interpretation</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">â€ </a>
</td>
</tr>
<tr>
<td>â‰¥ 26</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr><td colspan="2"><p class="First">Zone diameter interpretative standard for testing <span class="Italics">Neisseria gonorrhoeae</span>.Â <a name="footnote-reference-7" href="#footnote-7" class="Sup">â€¡</a></p></td></tr>
<tr>
<td><span class="Underline">Zone Diameter (mm)</span></td>
<td>
<span class="Underline">Interpretation</span>Â <a href="#footnote-6" class="Sup">â€ </a>
</td>
</tr>
<tr class="Last">
<td>â‰¥ 38</td>
<td>Susceptible (S)</td>
</tr>
</tbody>
</table>
<p>Interpretation should be as stated above for results using dilution techniques.  Interpretation involves correlation of the diameter obtained in the disk test with the MIC for ceftizoxime.</p>
<p>As with standardized dilution techniques, diffusion methods require the use of laboratory control microorganisms that are used to control the technical aspects of the laboratory procedures.  For the diffusion technique, the 30-Î¼g ceftizoxime disk should provide the following zone diameters in these laboratory test quality control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>:</p>
<a name="ID_EDE3065F-1D48-4DDE-96D6-EAB1406F1605"></a><table border="none" frame="void" width="440">
<col width="62.500%">
<col width="37.500%">
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top"><span class="Underline">Microorganism</span></td>
<td align="center" valign="top"><span class="Underline">Zone Diameter (mm)</span></td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Escherichia coli  </span>ATCC 25922</td>
<td align="center" valign="top">30-36</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Haemophilus influenzae  </span>ATCC 49247</td>
<td align="center" valign="top">29-39</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Neisseria gonorrhoeae  </span>ATCC 49226</td>
<td align="center" valign="top">42-51</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Pseudomonas aeruginosa  </span>ATCC 27853</td>
<td align="center" valign="top">12-17</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Italics">Staphylococcus aureus</span>  ATCC 25923</td>
<td align="center" valign="top">27-35</td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_7D3FB680-90B2-41D9-83E2-BD2BD684F5CE"></a><a name="section-5.2.3"></a><p></p>
<h3>Â Anaerobic Techniques:</h3>
<p class="First">For anaerobic bacteria, the susceptibility to ceftizoxime as MICs can be determined by standardized test methods.  Agar dilution results can vary widely when using ceftizoxime.  It is recommended that broth microdilution method be used when possible.<span class="Sup">3 </span> The MIC values obtained should be interpreted according to the following criteria:</p>
<a name="ID_08837251-44F6-4584-B6D8-BA47428CB0C4"></a><table width="0">
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td colspan="2"><span class="Bold Underline">MIC(Î¼<span class="Bold Underline">g/mL)</span></span></td>
<td></td>
</tr>
<tr>
<td><span class="Bold Underline">Broth dilution</span></td>
<td><span class="Bold Underline">Agar dilution</span></td>
<td><span class="Bold Underline">Interpretation</span></td>
</tr>
<tr>
<td>â‰¤ 16</td>
<td>â‰¤ 32</td>
<td>Susceptible (S)</td>
</tr>
<tr>
<td>32</td>
<td>64</td>
<td>Intermediate (I)</td>
</tr>
<tr class="Last">
<td>â‰¥ 64</td>
<td>â‰¥ 128</td>
<td>Resistant (R)</td>
</tr>
</tbody>
</table>
<p>Interpretation is identical to that described in Susceptibility Testing: Dilution Techniques.</p>
<p>As with other susceptibility techniques, the use of laboratory control microorganisms is required to control the technical aspects of the laboratory standardized procedures.  Standardized ceftizoxime powder should provide the following MIC values:</p>
<a name="ID_0E4973B1-59E2-49B6-B612-DCF01301C095"></a><table width="533">
<col width="50.469%">
<col width="24.765%">
<col width="24.765%">
<tbody class="Headless">
<tr class="First">
<td><p class="First"><span class="Bold Underline">Microorganism</span></p></td>
<td colspan="2"><span class="Bold Underline">MIC(Î¼g/mL)</span></td>
</tr>
<tr>
<td></td>
<td><span class="Bold Underline">Broth dilution</span></td>
<td><span class="Bold Underline">Agar dilution</span></td>
</tr>
<tr>
<td>
<span class="Italics Underline">Eubacterium lentum </span><span class="Italics Underline"> ATCC 43055</span>
</td>
<td>16-64</td>
<td>16-64</td>
</tr>
<tr class="Last">
<td>
<span class="Italics Underline">Bacteriodes thetaiotaomicron </span><span class="Italics Underline">ATCC 29741</span>
</td>
<td>---</td>
<td>4-16</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_BB660676-E862-4005-87F3-5EBCA1DE22CC"></a><a name="section-5.3"></a><p></p>
<h2>Â Susceptibility Testing for PseuÂ domonas in <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span></h2>
<p class="First">Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas aeruginosa</span> are moderately susceptible to ceftizoxime.  </p>
<p>Ceftizoxime achieves high levels in the urine (greater than 6000 mcg/mL at 2 hours with</p>
<p>1 gram IV) and, therefore, the following zone sizes should be used when testing </p>
<p>ceftizoxime for treatment of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> caused by <span class="Italics">Pseudomonas</span></p>
<p><span class="Italics">aeruginosa</span>.</p>
<p>Susceptible organisms produce zones of 20 mm or greater, indicating that the</p>
<p>test organism is likely to respond to therapy.</p>
<p>Organisms that produce zones of 11 to 19 mm are expected to be susceptible</p>
<p>when the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confined to the urinary tract (in which high antibiotic levels</p>
<p>are attained). </p>
<p>Resistant organisms produce zones of 10 mm or less, indicating that other </p>
<p>therapy should be selected.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_EBB5F71B-D45D-474D-9BF0-9737E3935B45"></a><a name="section-6"></a><p></p>
<h1>Indications and Usage</h1>
<p class="First">Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the microorganisms listed below.</p>
<p><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span> caused by<span class="Italics"> Klebsiella</span> spp.; <span class="Italics">Proteus mirabilis</span>; <span class="Italics">Escherichia coli; Haemophilus influenzae</span> including ampicillinâ€?resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>; <span class="Italics">Staphylococcus aureus</span> (penicillinaseÂ­ and nonpenicillinaseâ€?producing); <span class="Italics">Serratia</span> spp.; <span class="Italics">Enterobacter</span> spp.; <span class="Italics">Bacteroides</span> spp.; and <span class="Italics">Streptococcus</span> spp. including <span class="Italics">S. pneumoniae</span>, but excluding enterococci.</p>
<p><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> caused by <span class="Italics">Staphylococcus aureus</span> (penicillinaseâ€? and nonpenicillinaseâ€?producing); <span class="Italics">Escherichia coli</span>; <span class="Italics">Pseudomonas</span> spp. including <span class="Italics">P.</span><span class="Italics">aeruginosa</span>; <span class="Italics">Proteus mirabilis</span>; <span class="Italics">P. vulgaris</span>; <span class="Italics">Providencia rettgeri</span> (formerly <span class="Italics">Proteus rettgeri</span>) and <span class="Italics">Morganella morganii</span> (formerly <span class="Italics">Proteus morganii</span>); <span class="Italics">Klebsiella</span> spp.; <span class="Italics">Serratia</span> spp. including <span class="Italics">S. marcescens</span>; and <span class="Italics">Enterobacter</span> spp.</p>
<p><span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span> including uncomplicated cervical and urethral <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> caused by <span class="Italics">Neisseria gonorrhoeae</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">Pelvic Inflammatory Disease</span> caused by <span class="Italics">Neisseria gonorrhoeae, Escherichia coli</span> or <span class="Italics">Streptococcus agalactiae</span>. </p>
<p>NOTE: Ceftizoxime, like other cephalosporins, has no activity against <span class="Italics">Chlamydia trachomatis</span>. Therefore, when cephalosporins are used in the treatment of patients with <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> and <span class="Italics">C. trachomatis</span> is one of the suspected pathogens, appropriate antiÂ­chlamydial coverage should be added.</p>
<p>Intraâ€?<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span> caused by <span class="Italics">Escherichia coli; Staphylococcus</span><span class="Italics">epidermidis; Streptococcus</span> spp. (excluding enterococci); <span class="Italics">Enterobacter</span> spp.; <span class="Italics">Klebsiella</span> spp.; <span class="Italics">Bacteroides</span> spp. including  <span class="Italics">B. fragilis</span>; and anaerobic cocci, including <span class="Italics">Peptococcus</span> spp. and <span class="Italics">Peptostreptococcus</span> spp.</p>
<p><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span> caused by <span class="Italics">Streptococcus</span> spp. including <span class="Italics">S. pneumoniae</span> (but excluding enterococci); <span class="Italics">Staphylococcus aureus</span> (penicillinaseâ€? and nonpenicillinaseâ€?producing); <span class="Italics">Escherichia coli; Bacteroides</span> spp. including <span class="Italics">B. fragilis</span>; <span class="Italics">Klebsiella</span> spp.; and <span class="Italics">Serratia</span> spp.</p>
<p>Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by <span class="Italics">Staphylococcus aureus</span> (penicillinaseâ€? and nonpenicillinaseâ€?producing); <span class="Italics">Staphylococcus epidermidis</span>; <span class="Italics">Escherichia coli; Klebsiella</span> spp.; <span class="Italics">Streptococcus</span> spp. including <span class="Italics">Streptococcus pyogenes</span> (but excluding enterococci); <span class="Italics">Proteus mirabilis</span>; <span class="Italics">Serratia</span> spp.; <span class="Italics">Enterobacter</span> spp.; <span class="Italics">Bacteroides</span> spp. including <span class="Italics">B. fragilis</span>; and anaerobic cocci, including <span class="Italics">Peptococcus</span> spp. and <span class="Italics">Peptostreptococcus</span> spp.</p>
<p>Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">Joint Infections</span> caused by <span class="Italics">Staphylococcus aureus</span> (penicillinaseâ€? and nonpenicillinaseâ€?producing); <span class="Italics">Streptococcus</span> spp. (excluding enterococci); <span class="Italics">Proteus</span><span class="Italics">mirabilis</span>; <span class="Italics">Bacteroides</span> spp.; and anaerobic cocci, including <span class="Italics">Peptococcus</span> spp. and <span class="Italics">Peptostreptococcus</span> spp.</p>
<p><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span> caused by <span class="Italics">Haemophilus influenzae</span>. Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> caused by <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p>Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. </p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> caused by aerobic gramâ€?negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox.</p>
<p>Because of the serious nature of some <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> due to <span class="Italics">P. aeruginosa</span> and because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas</span> species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt.</p>
<p>Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, Cefizox has been used concomitantly with aminoglycosides (see <a href="#i4i_precautions_ID_88B7CEFE-4B8F-4151-90C0-47711423EA25">PRECAUTIONS</a>). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_F04EC45C-5F20-468E-B091-0585726168D2"></a><a name="section-7"></a><p></p>
<h1>Contraindications</h1>
<p class="First">Cefizox (ceftizoxime for injection, USP) is contraindicated in patients who have known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the drug.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_65014490-1303-4C6D-B198-6E98455A0064"></a><a name="section-8"></a><p></p>
<h1>Warnings</h1>
<p class="First"><span class="Bold">BEFORE THERAPY WITH CEFIZOX IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEFIZOX, OTHER CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLINÂ­SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> AMONG BETAâ€?LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">PENICILLIN ALLERGY</span>. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFIZOX OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> has been reported with nearly all antibacterial agents, including ceftizoxime, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> subsequent to the administration of antibacterial agents.</span></p>
<p>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <span class="Italics">Clostridium difficile</span> is a primary cause of â€œantibioticâ€?associatedâ€? <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>After the diagnosis of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> has been established, appropriate therapeutic measures should be initiated. Mild cases of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> usually respond to drug discontinuation alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against <span class="Italics">Clostridium difficile</span> <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_88B7CEFE-4B8F-4151-90C0-47711423EA25"></a><a name="section-9"></a><p></p>
<h1>Precautions</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_E05D6DC5-B8CA-4CD2-B125-DB9AE39E5121"></a><a name="section-9.1"></a><p></p>
<h2>General</h2>
<p class="First">As with all broadâ€?spectrum antibiotics, Cefizox (ceftizoxime for injection, USP) should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>Although Cefizox has not been shown to produce an alteration in renal function, renal status should be evaluated, especially in seriously ill patients receiving maximum dose therapy. As with any antibiotic, prolonged use may result in overgrowth of nonsusceptible organisms. Careful observation is essential; appropriate measures should be taken if <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs.</p>
<p>Cephalosporins may be associated with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity.  Those at risk include patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy.  <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be monitored in patients at risk and exogenous vitamin K administered as indicated.</p>
<p>Prescribing Cefizox in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_36C6C4AF-B545-4C16-99A9-C21223961F01"></a><a name="section-9.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Although the occurrence has not been reported with Cefizox, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> has been reported following concomitant administration of other cephalosporins and aminoglycosides.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_53AB19C8-06CB-43CE-8DCA-19A57DB2FF3A"></a><a name="section-9.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Longâ€?term studies in animals to evaluate the carcinogenic potential of ceftizoxime have not been conducted. </p>
<p>In an <span class="Italics">in vitro</span> bacterial cell assay (i.e., Ames test), there was no evidence of mutagenicity at ceftizoxime concentrations of 0.001â€?0.5 mcg/plate. Ceftizoxime did not produce increases in micronuclei in the <span class="Italics">in vivo</span> mouse micronucleus test when given to animals at doses up to 7500 mg/kg, approximately six times greater than the maximum human daily dose on a mg/M<span class="Sup">2</span> basis.</p>
<p>Ceftizoxime had no effect on fertility when administered subcutaneously to rats at daily doses of up to 1000 mg/kg/day, approximately two times the maximum human daily dose on a mg/M<span class="Sup">2</span> basis. Ceftizoxime produced no histological changes in the sexual organs of male and female dogs when given intravenously for thirteen weeks at a dose of 1000 mg/kg/day, approximately five times greater than the maximum human daily dose on a mg/M<span class="Sup">2</span> basis.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_B5F5A16C-A0B5-44C4-828B-CB5C9D6DA430"></a><a name="section-9.4"></a><p></p>
<h2>Pregnancy: </h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_ID_7EB36115-E412-4249-94EE-9D09799B7C27"></a><a name="section-9.5"></a><p></p>
<h2>Teratogenic Effects: </h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_pregnancy_B_ID_863D7B5C-DC37-4B76-AB56-73F2C938C719"></a><a name="section-9.6"></a><p></p>
<h2>Pregnancy Category B.</h2>
<p class="First">Reproduction studies performed in rats and rabbits have revealed no evidence of impaired fertility or harm to the fetus due to Cefizox. There are, however, no adequate and wellâ€?controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human effects, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_ID_20A3291D-B4EC-4D4F-8A40-F69B4DFE792C"></a><a name="section-9.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Safety of Cefizox use during labor and delivery has not been established.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_093583D3-0E98-4B15-85CD-676B8C96B6D2"></a><a name="section-9.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Cefizox is excreted in human milk in low concentrations. Caution should be exercised when Cefizox is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_6121982E-5BAD-498E-BC72-CC6B7314060A"></a><a name="section-9.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and efficacy in pediatric patients from birth to six months of age have not been established. In pediatric patients six months of age and older, treatment with Cefizox has been associated with transient elevated levels of eosinophils, AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), ALT (SGPT), and CPK (creatine phosphokinase). The CPK elevation may be related to IM administration.</p>
<p>The potential for the toxic effect in pediatric patients from chemicals that may leach from the singleâ€?dose IV preparation in plastic has not been determined.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_E652F7D2-65CE-43EA-9EFE-A1990E0EA2AA"></a><a name="section-9.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of ceftizoxime did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in responses between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_E5B7D72F-76CB-432F-9A20-9F454C19A661"></a><a name="section-9.11"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be counseled that antibacterial drugs including Cefizox should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When Cefizox is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefizox or other antibacterial drugs in the future.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_9B255C3F-3734-44AB-9E88-08B96E764054"></a><a name="section-10"></a><p></p>
<h1>Adverse Reactions</h1>
<p class="First">Cefizox<span class="Sup">Â®</span> (ceftizoxime for injection, USP) is generally well tolerated. The <span class="Italics">most</span> frequent adverse reactions (<span class="Italics">greater</span> than 1% but <span class="Italics">less</span> than 5%) are:</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>--<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
<p>Hepatic--Transient elevation in AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), ALT (SGPT), and alkaline phosphatase.</p>
<p>Hematologic--Transient <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>. Some individuals have developed a positive Coombs test.</p>
<p>Local--Injection site--Burning, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span> with IV administration, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.</p>
<p>The <span class="Italics">less</span> frequent adverse reactions (<span class="Italics">less</span> than 1%) are:</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>--<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported rarely.</p>
<p>Hepatic--Elevation of bilirubin has been reported rarely.</p>
<p>Renal--Transient elevations of BUN and creatinine have been occasionally observed with Cefizox.</p>
<p>Hematologic--<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, including <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span> with occasional fatal outcome, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> have been reported rarely.</p>
<p>Urogenital--<span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">Vaginitis</span> has occurred rarely.</p>
<p>Gastrointestinal--<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have been reported occasionally.</p>
<p>Symptoms of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> can appear during or after antibiotic treatment (see <a href="#i4i_warnings_ID_65014490-1303-4C6D-B198-6E98455A0064">WARNINGS</a>).</p>
<p>In addition to the adverse reactions listed above which have been observed in patients treated with ceftizoxime, the following adverse reactions and altered laboratory tests have been reported for cephalosporinâ€?class antibiotics:</p>
<p>Stevensâ€?Johnson syndrome, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, serumâ€?sickness like reaction, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, elevated LDH, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
<p>Several cephalosporins have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, when the dosage was not reduced. (See <span class="Bold"><a href="#i4i_dosage_admin_ID_AC17F8AB-3F3C-4019-9392-94F31600E3BA">DOSAGE AND ADMINISTRATION</a></span>.) If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_AC17F8AB-3F3C-4019-9392-94F31600E3BA"></a><a name="section-11"></a><p></p>
<h1>Dosage and Administration</h1>
<p class="First">Note:  Cefizox (ceftizoxime for injection, USP) in the ADD-VantageÂ®Â  vial is intended for intravenous infusion only after dilution with the appropriate volume of ADD-Vantage diluent solution.</p>
<p>The usual adult dosage is 1 or 2 grams of Cefizox (ceftizoxime for injection, USP) every 8 to 12 hours. Proper dosage and route of administration should be determined by the condition of the patient, severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and susceptibility of the causative organisms.</p>
<a name="ID_AA53EEF0-CE3A-4DAF-B624-3B2F79F5FB00"></a><table width="0">
<caption><span>General Guidelines for Dosage of Cefizox</span></caption>
<col>
<col>
<col>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>When administering 2 gram IM doses, the dose should be divided and given in different large <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle masses</span>.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">â€ </a></dt>
<dd>If <span class="Italics">C. trachomatis</span> is a suspected pathogen, appropriate antiÂ­chlamydial coverage should be added, because ceftizoxime has no activity against this organism.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">â€¡</a></dt>
<dd>In lifeâ€?threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, dosages up to 2 grams every 4 hours have been given.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td>
<p class="First">Type of</p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td>
<p class="First">Daily Dose</p>(Grams)</td>
<td>
<p class="First">Frequency</p>and Route</td>
</tr>
<tr>
<td>Uncomplicated </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary Tract</td>
<td>1</td>
<td>500 mg q12h IM or IV</td>
</tr>
<tr>
<td>Other Sites</td>
<td>2-3</td>
<td>1 gram q8-12h IM or IV</td>
</tr>
<tr>
<td>Severe or </td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refractory</td>
<td>3-6</td>
<td>1 gram q8h IM or IV</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 grams q8-12h IM<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a> or IV</td>
</tr>
<tr>
<td>PIDÂ <a name="footnote-reference-9" href="#footnote-9" class="Sup">â€ </a>
</td>
<td>6</td>
<td>2 grams q8h IV</td>
</tr>
<tr class="Last">
<td>Life-ThreateningÂ <a name="footnote-reference-10" href="#footnote-10" class="Sup">â€¡</a>
</td>
<td>9-12</td>
<td>3-4 grams q8h IV</td>
</tr>
</tbody>
</table>
<p>Because of the serious nature of <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> due to <span class="Italics">P. aeruginosa</span> and because many <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Pseudomonas</span> species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. </p>
<p>A single, 1 gram IM dose is the usual dose for treatment of uncomplicated <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span>.</p>
<p>The IV route may be preferable for patients with bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, localized parenchymal <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span> (such as intraÂ­<span class="product-label-link" type="condition" conceptid="4326255" conceptname="Abdominal abscess">abdominal abscess</span>), <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, or other severe or lifeâ€?threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>In those with normal renal function, the IV dosage for such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is 2 to 12 grams of Cefizox (ceftizoxime for injection, USP) daily. In conditions such as bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>, 6 to 12 grams/day may be given initially by the IV route for several days, and the dosage may then be gradually reduced according to clinical response and laboratory findings.</p>
<a name="ID_1A899373-53CE-4783-A25D-831BC4740143"></a><table width="0">
<caption><span>Pediatric Dosage Schedule</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td></td>
<td>Unit Dose</td>
<td>Frequency</td>
</tr>
<tr class="Last">
<td>
<p class="First">Pediatric patients</p>6 months or older</td>
<td>50 mg/kg</td>
<td>q6-8h</td>
</tr>
</tbody>
</table>
<p>Dosage may be increased to a total daily dose of 200 mg/kg (not to exceed the maximum adult dose for serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_BBBAAF48-B681-46F2-B306-2C76522356DF"></a><a name="section-11.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Modification of Cefizox dosage is necessary in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Following an initial loading dose of 500 mg-1 gram IM or IV, the maintenance dosing schedule shown below should be followed. Further dosing should be determined by therapeutic monitoring, severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and susceptibility of the causative organisms.</p>
<p>When only the serum creatinine level is available, creatinine clearance may be calculated from the following formula. The serum creatinine level should represent current renal function at the steady state.</p>
<p>Males</p>
<a name="ID_515A4165-A55A-417E-A09F-4E9BDFFB8B76"></a><table width="225">
<col width="26.667%">
<col width="73.333%">
<tbody class="Headless">
<tr class="First">
<td><p class="First">Clcr =</p></td>
<td align="center"><p class="First"><span class="Underline">Weight (kg) x (140 Â­ age)</span></p></td>
</tr>
<tr>
<td></td>
<td align="center"><p class="First">72 x serum creatinine</p></td>
</tr>
<tr class="Last">
<td></td>
<td align="center"><p class="First">(mg/100 mL)</p></td>
</tr>
</tbody>
</table>
<p>Females are 0.85 of the calculated clearance values for males.</p>
<p>In patients undergoing hemodialysis, no additional supplemental dosing is required following hemodialysis; however, dosing should be timed so that the patient receives the dose (according to the table below) at the end of the dialysis.</p>
<a name="ID_CD7ABF86-702A-405A-A66A-A631893E09F8"></a><table width="0">
<caption><span>Dosage in Adults with Reduced Renal Function</span></caption>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td>
<p class="First">Creatinine</p>
<p>Clearance</p>mL/min</td>
<td>
<p class="First">Renal </p>Function</td>
<td>
<p class="First">Less Severe</p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></td>
<td>
<p class="First">Life-Threatening</p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></td>
</tr>
<tr>
<td>79-50</td>
<td>
<p class="First">Mild</p>Impairment</td>
<td>500 mg q8h</td>
<td>
<p class="First">0.75-1.5 grams</p>q8h</td>
</tr>
<tr>
<td>49-5</td>
<td>
<p class="First">Moderate </p>
<p>to severe</p>impairment</td>
<td>
<p class="First">250-500 mg</p>q12h</td>
<td>
<p class="First">0.5-1 gram</p>q12h</td>
</tr>
<tr class="Last">
<td>4-0</td>
<td>
<p class="First">Dialysis</p>Patients</td>
<td>
<p class="First">500 mg q48h</p>
<p>or</p>250 mg q24h</td>
<td>
<p class="First">0.5-1 gram</p>
<p>q48h</p>
<p>or</p>0.5 gram q24h</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_E71B731B-6CD8-4558-B2A8-5D7744A17053"></a><a name="section-11.2"></a><p></p>
<h2>Reconstitution</h2>
<p class="First">Cefizox in the ADD-Vantage vial is intended for use with ADD-Vantage diluent containers only, available in 50 mL and 100 mL sizes of Sodium Chloride Injection 0.9% and Dextrose Injection 5%.</p>
<p>Ordinarily, the ADD-Vantage vials should be reconstituted only when it is certain that the patient is ready to receive the drug.  However, reconstitued Cefizox is stable for 24 hours at room temperature or 96 hours under refrigeration 5Â°C (41Â°F).</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_3AA4468D-EDFB-42F9-B4B4-EEFC403B5292"></a><a name="section-11.3"></a><p></p>
<h2>To Open ADD-Vantage Â® Diluent Containers</h2>
<p class="First">Peel overwrap at corner and remove solution container.  Some opacity of the plastic due to moisture absorption during the sterilization process may be observed.  This is normal and does not affect the solution quality or safety.  The opacity will diminish gradually.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_35896D0A-303D-4822-9291-194F365D9374"></a><a name="section-11.4"></a><p></p>
<h2>To Assemble Vial and Flexible Diluent Container (Use Aseptic Technique)</h2>
<p class="First">1. Remove the protective covers from the top of the vial and the vial port on the diluent container as follows:<br></p>
<p>a.  To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (SEE FIGURE 1.), then pull straight up to remove the cap. (SEE FIGURE 2.)  </p>
<p>NOTE:  Once the breakaway cap has been removed, do not access vial with syringe.</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0013824B-6AEE-4DA4-AFFD-35BC6BF19D91&amp;name=cefizox-02.jpg"></div>
<p>b.  To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull further to remove the cover. (SEE FIGURE 3.)<br></p>
<p>2. Screw the vial into the vial port until it will go no further.  THE VIAL MUST BE SCREWED IN TIGHTLY TO ASSURE A SEAL.  This occurs approximately Â½ turn (180Â°) after the first audible click.  (SEE FIGURE 4.)  The clicking sound does not assure a seal; the vial must be turned as far as it will go.  NOTE: Once vial is sealed, do not attempt to remove. (SEE FIGURE 4.)</p>
<p>3. Recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly.</p>
<p>4. Label appropriately.</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0013824B-6AEE-4DA4-AFFD-35BC6BF19D91&amp;name=cefizox-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_929755B6-9973-4687-8574-51F7E8C8620F"></a><a name="section-11.5"></a><p></p>
<h2>To Prepare Admixture</h2>
<ol>
<li>Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial.</li>
<li>With the other hand, push the drug vial down into the container telescoping the walls of the container.  Grasp the inner cap of the vial through the walls of the container. (SEE FIGURE 5.)</li>
<li>Pull the inner cap from the drug vial.  (SEE FIGURE 6.) Verify that the rubber stopper has been pulled out, allowing the diluent to enter the drug vial and thoroughly dissolve the powder.</li>
<li>Mix container contents thoroughly by inverting several times, and use within the specified time.</li>
</ol>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0013824B-6AEE-4DA4-AFFD-35BC6BF19D91&amp;name=cefizox-04.jpg"></div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_9C7AE6E0-B87B-4C50-B034-E149F4FBA127"></a><a name="section-11.6"></a><p></p>
<h2>Preparation for Administration (Use Aseptic Technique)</h2>
<ol>
<li>Confirm the activation and admixture of vial contents.</li>
<li>Check for leaks by squeezing container firmly.  If leaks are found, discard unit as  <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be impaired.</li>
<li>Close flow control clamp of administration set.</li>
<li>Remove cover from outlet port at bottom of container.</li>
<li>Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated.  NOTE: See full directions on administration set carton.</li>
<li>Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings.  Bend the loop outward to lock it in the upright position, then suspend container from hanger.  </li>
<li>Squeeze and release drip chamber to establish proper fluid level in chamber.</li>
<li>Open flow control clamp and clear air from set.  Close clamp.</li>
<li>Attach set to venipuncture device.  If device is not indwelling, prime and make venipuncture. </li>
<li>Regulate rate of administration with flow control clamp.</li>
</ol>
<p class="First"><span class="Bold">WARNING: Do not use flexible container in series connections.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_1332A986-7684-4BD4-9E0A-AABA2F354AB0"></a><a name="section-12"></a><p></p>
<h1>How Supplied</h1>
<p class="First">Cefizox<span class="Sup">Â®</span> (ceftizoxime for injection, USP) in ADD-Vantage<span class="Sup">Â®</span> Vials</p>
<a name="ID_DE4EFCD7-0916-4F06-8B84-B0F76928333C"></a><table width="505">
<col width="61.980%">
<col width="38.020%">
<tbody class="Headless">
<tr class="First">
<td>NDC 0469-7271-01  </td>
<td>Product No. 727101</td>
</tr>
<tr>
<td><p class="First">equivalent to 1 gram ceftizoxime, packaged in tens</p></td>
<td></td>
</tr>
<tr>
<td>NDC 0469-7272-02  </td>
<td>  Product No. 727202</td>
</tr>
<tr class="Last">
<td><p class="First">equivalent to 2 grams ceftizoxime, packaged in tens</p></td>
<td></td>
</tr>
</tbody>
</table>
<p>Unreconstituted Cefizox should be protected from excessive light, and stored at controlled room temperature 15Â°-30Â°C (59Â°-86Â°F) in the original package until used.</p>
<p>ADD-Vantage<span class="Sup">Â®</span> is registered trademark of Abbott Laboratories.</p>
<p>U.S. Patent 4,427,674</p>
<p>Product of Japan</p>
<p>REFERENCES</p>
<ol>
<li>National Committee for Clinical Laboratory Standards.  Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically â€“ Fifth Edition.  Approved Standard NCCLS Document M7-A5, Vol. 20, No. 2, NCCLS, Wayne, PA, January 2000.</li>
<li>National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests â€“ Seventh Edition.  Approved Standard NCCLS Document M2-A7, Vol. 20, No. 1, NCCLS, Wayne, PA, January 2000.</li>
<li>National Committee for Clinical Laboratory Standards.  Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria â€“ Fourth Edition.  Approved Standard NCCLS Document M11-A4, Vol. 17, No. 22, NCCLS, Wayne, PA, December 1997.</li>
<li>National Committee for Clinical Laboratory Standards. MIC Testing Supplemental Tables.  NCCLS Document M100-S10 (M7), NCCLS, Wayne, PA, January 2000.</li>
</ol>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_EFAF3E8B-4D73-4D5D-8CF0-8E5419963AB1"></a><a name="section-12.1"></a><p></p>
<h2>Rx only</h2>
<p class="First">Manufactured for Fujisawa Healthcare, Inc.</p>
<p>Deerfield, IL 60015-2548 by GlaxoSmithKline, Philadelphia, PA  19101</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFIZOXÂ 		
					</strong><br><span class="contentTableReg">ceftizoxime injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0469-7271</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ceftizoxime sodium</strong> (ceftizoxime) </td>
<td class="formItem"></td>
<td class="formItem">1Â g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0469-7271-01</td>
<td class="formItem">10  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFIZOXÂ 		
					</strong><br><span class="contentTableReg">ceftizoxime injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0469-7272</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ceftizoxime sodium</strong> (ceftizoxime) </td>
<td class="formItem"></td>
<td class="formItem">2Â g</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0469-7272-02</td>
<td class="formItem">10  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Fujisawa Healthcare, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2006<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0013824B-6AEE-4DA4-AFFD-35BC6BF19D91</div>
<div>Set id: 0013824B-6AEE-4DA4-AFFD-35BC6BF19D91</div>
<div>Version: 1</div>
<div>Effective Time: 20060608</div>
</div>
</div>Â <div class="DistributorName">Fujisawa Healthcare, Inc.</div></p>
</body></html>
